These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 15798492)

  • 21. Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.
    Johanson JF
    Neurogastroenterol Motil; 2004 Dec; 16(6):701-11. PubMed ID: 15601419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of the irritable bowel syndrome.
    Camilleri M
    Gastroenterology; 2001 Feb; 120(3):652-68. PubMed ID: 11179242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update in the therapeutic management of irritable bowel syndrome.
    Villanueva A; Domínguez-Muñoz JE; Mearin F
    Dig Dis; 2001; 19(3):244-50. PubMed ID: 11752844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB; Wilhelm SM
    Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drugs acting on serotonin receptors for the treatment of functional GI disorders.
    Tonini M; Pace F
    Dig Dis; 2006; 24(1-2):59-69. PubMed ID: 16699264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
    Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2008 Clinical approach to irritable bowel syndrome.
    Astegiano M; Pellicano R; Sguazzini C; Berrutti M; Simondi D; Reggiani S; Rizzetto M
    Minerva Gastroenterol Dietol; 2008 Sep; 54(3):251-7. PubMed ID: 18614974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
    Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
    Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.
    Chey WD; Cash BD
    Expert Opin Investig Drugs; 2005 Feb; 14(2):185-93. PubMed ID: 15757394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of serotonin in gastrointestinal motility and irritable bowel syndrome.
    Sikander A; Rana SV; Prasad KK
    Clin Chim Acta; 2009 May; 403(1-2):47-55. PubMed ID: 19361459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Serotonin Receptor Ligands in the Treatment of Irritable Bowel Syndrome: A Review.
    Binienda A; Storr M; Fichna J; Salaga M
    Curr Drug Targets; 2018; 19(15):1774-1781. PubMed ID: 29284389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tegaserod: a serotonin 5-HT4 receptor agonist for treatment of constipation-predominant irritable bowel syndrome.
    Cole P; Rabasseda X
    Drugs Today (Barc); 2004 Dec; 40(12):1013-30. PubMed ID: 15645012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tegaserod for the Treatment of Irritable Bowel Syndrome.
    Madia VN; Messore A; Saccoliti F; Tudino V; De Leo A; De Vita D; Bortolami M; Scipione L; Pindinello I; Costi R; Di Santo R
    Antiinflamm Antiallergy Agents Med Chem; 2020; 19(4):342-369. PubMed ID: 31518227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
    Lewis JH
    Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):13-29. PubMed ID: 20136586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective.
    Tack J; Fried M; Houghton LA; Spicak J; Fisher G
    Aliment Pharmacol Ther; 2006 Jul; 24(2):183-205. PubMed ID: 16842448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenesis and management of irritable bowel syndrome.
    Mathew P; Bhatia SJ
    Trop Gastroenterol; 2009; 30(1):19-25. PubMed ID: 19624083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging pharmacological therapies for the irritable bowel syndrome.
    Maneerattanaporn M; Chang L; Chey WD
    Gastroenterol Clin North Am; 2011 Mar; 40(1):223-43. PubMed ID: 21333909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
    Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG
    Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tegaserod and other serotonergic agents: what is the evidence?
    Chey WD
    Rev Gastroenterol Disord; 2003; 3 Suppl 2():S35-40. PubMed ID: 12776001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.